View on market: Volatility Prevails, Market is searching for better value
Markets in Asia-Pacific region rose as better than expected US GDP data affirmed investors’ expectation of a rate cut from the US Federal Reserve in September. Wall Street traders, confident in the Fed’s ability to orchestrate a smooth economic adjustment, fueled a rally in higher-risk sectors of the market. This comes after a widespread market downturn that shook global markets in the previous session. Shares of economically sensitive sectors, including financial and industrial companies, led the charge on Thursday. Smaller firms continued their strong performance this month, surging nearly 10%, significantly outpacing the gains of tech giants. The Indian benchmark equity indices ended little changed on Thursday as shares of Tata Motors Ltd. and HDFC Bank Ltd helped them erase losses after a lower open.
Economic Calendar:
- USD : PCE price index on 26 July
- IND: Fx reserves USD announcement on 26 July
- FOMC meeting on 31st July
Brokerage Radar:
Morgan Stanley on Cyient:
Downgrades to Underweight from Overweight; cuts target price to Rs 1,550 from Rs 2,250.Expect risk to the revised revenue guidance given high ask rate and weak track record. Expect stock to inch closer to last five-year average P/E.EPS CAGR for F24-26 at 1.6%
UBS on Tata Power:
Initiates Buy with target price of Rs 510.Sector opportunities’ robust expansion on climate and shortages. Valuations reasonable given the size of overall opportunities in the renewables space and its leadership position.
Macquarie on Ashok Leyland:
Maintains Neutral with target price of Rs 220.Q1FY25: In-line quarter; Margins improve YoΥ. Continues to outperform peers on growth with 7% YoY MHCV volume growth. Going ahead, competitive intensity and ability to retain / grow market share is key.
International Markets:
U.S & Europe:
Particulars | 25thJuly | Chg. | Chg.(%) |
Nasdaq | 17181.72 | -160.09 | -0.93 |
Dow | 39935.07 | 81.20 | 0.20 |
FTSE | 8186.35 | 32.66 | 0.40 |
CAC | 7427.02 | -86.71 | -1.17 |
DAX | 18298.72 | -88.74 | -0.48 |
Dow Fut.* | 40338 | 146 | 0.36 |
*As per26th July.
Asian markets:
Particulars | 26th July | Chg. | Chg.(%) |
GIFT Nifty | 24485 | 23.50 | 0.10 |
Nikkei | 38057.61 | 188.10 | 0.50 |
Straits Times | 3427.01 | -3.44 | -0.10 |
Hang Seng | 17132.19 | 127.22 | 0.75 |
Shanghai | 2881.40 | -2.43 | -0.08 |
Stocks strong on Chart:
Index | F&O | Cash |
BPCL | HINDPETRO | KEC INT |
TCS | ABIRLA FAS | DCX SYS |
LT | AURO PHA | SOLAR IND |
NTPC | TATA POWER | EXICOM |
ONGC | IOC | ORIENT CEM |
TATAMOT | INDIGO | TEXMACO RAIL |
Commodities & Currency:
Particulars | Current Price | Chg.(%) |
USD/INR | 83.74 | 0.02 |
Brent | 82.58 | 0.23 |
Gold | 67472 | 0.01 |
Silver | 81505 | -3.99 |
FIIs & DIIs:
Particulars | 25July | 24July |
FIIs | -2605.49 | -5130.90 |
DIIs | 2431.69 | 3137.30 |
News Update:
Company
Cupid | The company has expanded its E-commerce presence through Indian platforms like Amazon, Flipkart. |
SJVN | The company has received a huge order worth Rs 13,497 crore from the Government of Mizoram to complete a pumped storage project. |
Magadh Sugar & Energy | Sudershan Bajaj resigned as CFO and Key Managerial Personnel effective July 31 |
Mankind Pharma | The company will buy Bharat Serums and Vaccines for Rs 13,630 crore. The transaction is expected to close within 3–4 months |
GandharOil Refinery | The Board approved the incorporation of a new subsidiary, Gandhar Lifesciences. The new unit will carry out the pharmaceuticals and cosmetics business |
Source: Moneycontrol, Bloomberg Quint, Investing
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Kiran Tahlani, Elite Wealth Limited, kirantahlani@elitestock.com
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
- Reports
- a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
- Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.